Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Idera Pharmaceuticals, Inc."
Count: 15
Selected: 0
NCT IDTitle
NCT01899729A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis
NCT03865082Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
NCT03445533A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
NCT02644967A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma
NCT03052205A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
NCT02612857Trial of IMO-8400 in Adult Patients With Dermatomyositis
NCT02092909Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
NCT00990938Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients
NCT00728936Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients
NCT00729053Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
NCT02363439Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401
NCT01622348Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis
NCT02252146Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation
NCT04196283A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT04126876A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma